Replies to post #172993 on Biotech Values

[DewDiligence]

One indirect way is to look at what's happening to Pegasys post Sovaldi launch and infer the split from that.

That’s what analysts will probably try to do if GILD doesn’t furnish Sovaldi’s genotype breakdown.

What’s your estimate of the proportion of Sovaldi patient starts in 2014 that will be for GT1?